期刊
CURRENT OPINION IN CHEMICAL ENGINEERING
卷 31, 期 -, 页码 -出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.coche.2021.100673
关键词
-
资金
- Iowa State University Nanovaccine Institute
- N.I.H. [ES026892, U01 NS112008]
Synucleinopathies are debilitating neurodegenerative disorders with no clinically approved therapeutic options. Multiple synergistic pathological mechanisms and misfolding of proteins contribute to disease progression, making treatment challenging. Nanocarriers can improve brain delivery of therapeutics and enable multifunctional therapies.
Synucleinopathies are a subset of debilitating neurodegenerative disorders for which clinically approved therapeutic options to either halt or retard disease progression are currently unavailable. Multiple synergistic pathological mechanisms in combination with the characteristic misfolding of proteins are attributable to disease pathogenesis and progression. This complex interplay, as well as the difficult and multiscale nature of therapeutic delivery into the central nervous system, make finding effective treatments difficult. Nanocarriers (NCs) are a class of materials that can significantly improve therapeutic brain delivery and enable multifunctional therapies. In this review, an update on the known pathology of synucleinopathies is presented. Then, NC-enabled therapeutics designed to target the multiple mechanisms by combination therapies and multiscale targeting methods is reviewed. The implications of these strategies are synthesized and evaluated to suggest opportunities for the rational design of anti-neurodegenerative NC therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据